Back to resultsEffect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
Primary Purpose
Short Bowel Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
GLP-2
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Short Bowel Syndrome focused on measuring mesenteric blood flow, GLP-2, short bowel syndrome, Glucagon-Like Peptide 2
Eligibility Criteria
Inclusion Criteria:
- clinical diagnose of short bowel syndrome 4 month of stable fase
Exclusion Criteria:
- activity in IBD
Sites / Locations
- Glostrup University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
2
1
Arm Description
subcutaneous isotonic saline
subcutaneous GLP-2
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00673751
First Posted
May 5, 2008
Last Updated
May 6, 2008
Sponsor
Glostrup University Hospital, Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT00673751
Brief Title
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
Official Title
GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
May 2008
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Glostrup University Hospital, Copenhagen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome
Detailed Description
previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Short Bowel Syndrome
Keywords
mesenteric blood flow, GLP-2, short bowel syndrome, Glucagon-Like Peptide 2
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
N/A
Enrollment
8 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
subcutaneous isotonic saline
Arm Title
1
Arm Type
Active Comparator
Arm Description
subcutaneous GLP-2
Intervention Type
Drug
Intervention Name(s)
GLP-2
Intervention Description
450 nmol subcutaneous
Intervention Type
Drug
Intervention Name(s)
Placebo
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
clinical diagnose of short bowel syndrome 4 month of stable fase
Exclusion Criteria:
activity in IBD
Facility Information:
Facility Name
Glostrup University Hospital
City
Glostrup
State/Province
Region Hovedstaden
ZIP/Postal Code
2600
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
We'll reach out to this number within 24 hrs